Anemia and chronic kidney failure
Authors:
S. Štěpánková
Authors‘ workplace:
Centrum kardiovaskulární a transplantační chirurgie Brno, ředitel doc. MUDr. Petr Němec, CSc.
Published in:
Vnitř Lék 2011; 57(7&8): 631-634
Category:
136th internal medicine day, XXIV. Vanýskův den, Brno 2011
Overview
Anaemia is a common manifestation of a chronic kidney failure. It is caused by a relative shortage of erythropoetine (EPO) and iron deficite with its metabolism defect. The most important factor in the pathogenesis of iron metabolism defects is hepcidin. Hepcidin maintains the iron homeostasis in the organism. The therapy of renal anaemia is based on the iron substitution and erythropoiesis stimulating agents (ESA) application. The most common reasons for the resistance to ESA are (after iron deficiency) inflammation and malnutrition.
Key words:
chronic kidney failure – iron deficiency – hepcidin – erythropoiesis stimulating agents
Sources
1. Singh AK, Coyne DW, Shapiro W et al. Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int 2007; 71: 1163–1171.
2. Park CH, Valore EV, Waring AJ et al. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276: 7806–7810.
3. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia in inflammation. Blood 2003; 102: 783–788.
4. Nemeth E, Ganz T. Hepcidin and iron-loading anemias. Haematologica 2006; 91: 727–732.
5. Ganz T, Nemeth E. Iron sequestration and anemie of inflammation. Semin Hematol 2009; 46: 387–393.
6. Nemeth E, Valore EV, Territo M et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute phase protein. Blood 2003; 101: 2461–2463.
7. Rossert J, Casadevall N, Eckardt KU. Anti-erythropoietin antibodies and pure cell aplasia. J Am Soc Nephrol 2004; 15: 398–406.
8. Verhelst D, Rossert J, Casadevall N et al. Treatment of antibody-mediated pure red cell aplasia. J Am Soc Nephrol 2003; 14: 27A.
9. Macdougall IC, Cooper AC. Erythropoietin resistance: the role of inflammation and proinflammatory cytokines. Nephrol Dial Transplant 2002; 17 (Suppl II): 39–43.
10. Singh AK, Szczech L, Tang KL et al. CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085–2098.
11. Drüeke TB, Locatelli F, Clyne N et al. CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071–2084.
12. Pfeffer MA, Burdmann AE, Chen CY et al. A trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. N Engl J Med 2009; 361: 2019–2032.
13. Goldsmith D, Al-Khoury S, Shah N et al. Anemia after renal transplantation – role of immunosuppressive drugs and a pathophysiological appraisal. Nephron Clin Pract 2006; 104: c69–c74.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2011 Issue 7&8
Most read in this issue
- Haemodialysis – the current practice
- Anemia and chronic kidney failure
- Immunosuppressive therapy and its problems
- Aetiology and a clinical picture of chronic renal failure